VRTX Key Statistics, Chart & Performance
The current stock price of VRTX is 464.94 USD. In the past month the price decreased by -1.87%. In the past year, price increased by 9.58%.
VRTX Latest News, Press Relases and Analysis
VRTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.65 | 395.00B | ||
| AMGN | AMGEN INC | 15.07 | 177.48B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.13B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 797.37 | 53.72B | ||
| INSM | INSMED INC | N/A | 37.13B | ||
| NTRA | NATERA INC | N/A | 34.16B | ||
| BIIB | BIOGEN INC | 10.81 | 26.55B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.14 | 21.75B | ||
| INCY | INCYTE CORP | 16.67 | 21.01B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 15.35B |
Related stock screener links
About VRTX
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,100 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Company Info
VERTEX PHARMACEUTICALS INC
50 Northern Avenue
Boston MASSACHUSETTS 02210 US
CEO: Reshma Kewalramani
Employees: 6100
Phone: 16173416393
VERTEX PHARMACEUTICALS INC / VRTX FAQ
Can you describe the business of VERTEX PHARMACEUTICALS INC?
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,100 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
What is the current price of VRTX stock?
The current stock price of VRTX is 464.94 USD. The price increased by 3.6% in the last trading session.
What is the dividend status of VERTEX PHARMACEUTICALS INC?
VRTX does not pay a dividend.
What is the ChartMill rating of VERTEX PHARMACEUTICALS INC stock?
VRTX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the employee count for VRTX stock?
VERTEX PHARMACEUTICALS INC (VRTX) currently has 6100 employees.
What is the market capitalization of VRTX stock?
VERTEX PHARMACEUTICALS INC (VRTX) has a market capitalization of 117.96B USD. This makes VRTX a Large Cap stock.
Can you provide the ownership details for VRTX stock?
You can find the ownership structure of VERTEX PHARMACEUTICALS INC (VRTX) on the Ownership tab.
VRTX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to VRTX. When comparing the yearly performance of all stocks, VRTX turns out to be only a medium performer in the overall market: it outperformed 64.42% of all stocks.
VRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to VRTX. While VRTX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
VRTX Financial Highlights
Over the last trailing twelve months VRTX reported a non-GAAP Earnings per Share(EPS) of 17.36. The EPS increased by 3303.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.35% | ||
| ROA | 14.78% | ||
| ROE | 21.22% | ||
| Debt/Equity | 0 |
VRTX Forecast & Estimates
39 analysts have analysed VRTX and the average price target is 501.03 USD. This implies a price increase of 7.76% is expected in the next year compared to the current price of 464.94.
For the next year, analysts expect an EPS growth of 6343.89% and a revenue growth 10.14% for VRTX